KI-Beratung Beta

Gutscheinbedingungen

**Gültig bis 11.11.2026 auf Spielzeug, Schreibwaren, Filme, Geschenke & Trends, Musik, tolino eReader & Zubehör, Hörbücher und Hörbuch-Downloads, nicht preisgebundene Bücher und Kalender online auf thalia.at und in der Thalia App. Einzelne Artikel können ausgeschlossen sein. Aufgrund der Buchpreisbindung sind deutschsprachige Bücher und eBooks ausgenommen. Zusätzlich ausgenommen sind Abos & Flatrates, Games, Geschenkkarten/-boxen, Shelfies, Software, Zeitschriften sowie einzelne Artikel von tonies®. Pro Einkauf einmal einlösbar. Click & Collect nur bei Onlinevorabzahlung möglich. Keine Barauszahlung. Nicht kombinierbar mit anderen Aktionen und Gutscheinen. Gutschein wird auf max. 500€ Bestellwert angerechnet. Nicht gültig für Versandkosten und Services.

Produktbild: Advances in DNA and mRNA-Based Strategies for Cancer Immunotherapy: Part A
- 13%

Advances in DNA and mRNA-Based Strategies for Cancer Immunotherapy: Part A

Aus der Reihe Advances in Immunology
13% sparen

122,99 € UVP 141,90 €

inkl. gesetzl. MwSt., Versandkostenfrei


Beschreibung

Produktdetails

Einband

Gebundene Ausgabe

Erscheinungsdatum

18.06.2025

Herausgeber

Arun Kumar Singh + weitere

Verlag

Elsevier Science & Technology

Seitenzahl

208

Maße (B/H)

15,2/22,8 cm

Gewicht

470 g

Sprache

Englisch

ISBN

978-0-443-34495-4

Beschreibung

Portrait

Arun Kumar Singh is Assistant Professor in the Department of Pharmacy at the University School of Pharmaceutical Sciences, Rayat Bahra University, Sahauran, India. His research interests include nano-formulation, cancer biology, and neuroscience, alongside digital and computational approaches such as machine learning, artificial intelligence, big data analytics, blockchain, and the Internet of Things. He has contributed academic books, book chapters, and review articles in pharmaceutical sciences and healthcare technology, with a focus on interdisciplinary approaches that integrate pharmaceutical research with emerging digital technologies.

Neeraj Mishra is Professor and Head of the Department of Pharmaceutics at the Amity Institute of Pharmacy, Amity University Madhya Pradesh, Gwalior, India. His academic work focuses on novel drug delivery systems, including localized, targeted, and controlled delivery approaches using nanocarrier and microparticle-based technologies. His research interests encompass therapies for cancer and neurodegenerative disorders, and he has extensive experience in teaching, research supervision, and scholarly publishing. He has also contributed to innovation in pharmaceutical sciences through intellectual property development and collaborative academic activities. Through his research and educational initiatives, he supports the advancement of drug delivery strategies and pharmaceutical research.

Dr. Sumel Ashique has been working as an assistant professor at the Department of Pharmaceutical Technology, School of Health and Medical Sciences, Adamas University, West Bengal, India. He has 5 years of teaching experience. He has achieved 100+ publications in international and national accredited reputed journals. He has expertise in drug delivery, nanotechnology, and targeted treatment strategies. Recently, he was honored to be in the World's Top 2% Scientists by prestigious Stanford University, CA, United States, and Elsevier in 2025.

Pranav Kumar Prabhakar is Professor and Head of the Department of Biotechnology, School of Engineering and Technology, Nagaland University, Kohima, India. His research focuses on understanding molecular mechanisms involved in metabolic disorders, particularly diabetes, and on developing strategies for oral insulin delivery using natural products and biotechnology-based approaches. He is actively involved in research, academic mentoring, peer review, and editorial activities within the biomedical and biotechnology fields. His professional interests include translational research, signaling pathways associated with metabolic diseases, and the application of biotechnology to improve therapeutic outcomes. He contributes to scientific and academic initiatives that support advancements in biotechnology and healthcare research.

Produktdetails

Einband

Gebundene Ausgabe

Erscheinungsdatum

18.06.2025

Herausgeber

Verlag

Elsevier Science & Technology

Seitenzahl

208

Maße (B/H)

15,2/22,8 cm

Gewicht

470 g

Sprache

Englisch

ISBN

978-0-443-34495-4

EU-Ansprechpartner

Elsevier B.V.
Radarweg 29
1043 NX Amsterdam
NL
productsafety@elsevier.com

Herstelleradresse

Elsevier Science & Technology
London Wall 125
EC2Y 5AS London
GB
tradeorders@elsevier.com

Noch keine Bewertungen vorhanden

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.

Kundinnen und Kunden meinen

Bewertungen (0)

Die Leseprobe wird geladen.
  • Produktbild: Advances in DNA and mRNA-Based Strategies for Cancer Immunotherapy: Part A
  • 1. DNA and mRNA vaccines: Significant therapeutic approach against cancer management

    Aniruddha Sen, Vijay Singh, Sumel Ashique, Jagriti, Sombuddha Biswas, Anas Islam,

    Iman Ehsan, and Naheed Mojgani

    2. Nucleic acid delivery as a therapeutic approach for cancer immunotherapy

    Kashish Wilson, Garima, and Meenakshi Dhanawat

    3. Plasmid DNA and mRNA Delivery: Approaches and Challenges

    Arun Kumar Singh, Karan Goel, and Meenakshi Dhanawat

    4. Viral & non-viral delivery of mRNA against cancer

    Ece Guler, Humeyra Betul Yekeler, Muhammet Emin Cam, and Burcu Uner

    5. Progress in modifying and elivering mRNA therapies for cancer immunotherapy

    Karan Goel, Isha Chawla, Garima, Meenakshi Dhanawat, and Pramila Chaubey

    6. mRNA-based cancer vaccines: A novel approach to melanoma treatment

    Pranav Kumar Prabhakar, Tarun Kumar, Upadhyaya, and

    Sanjeev Kumar Sahu

    7. Therapeutic mRNAs for cancer immunotherapy: From structure to delivery

    Monika Vishwakarma, Wasim Akram, and Tanweer Haider